Yuan Xiu Zhou
Family · Flushing, NYNPI 1942722111
Payments from drug & device makers
Across 212 payments — averaging $30.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Amgen$915
- Novo Nordisk$738
- AbbVie$626
- Boehringer Ingelheim$464
- Madrigal Pharmaceuticals$271
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,392100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 48 | $1,749 |
| Amgen | 29 | $915 |
| Novo Nordisk | 23 | $738 |
| AbbVie | 33 | $626 |
| Boehringer Ingelheim | 12 | $464 |
| Madrigal Pharmaceuticals | 2 | $271 |
| Merck | 12 | $242 |
| Lilly USA, LLC | 7 | $226 |
| GSK | 4 | $179 |
| Nestle Healthcare Nutrition Inc. | 3 | $157 |
| Pfizer | 6 | $126 |
| AstraZeneca | 6 | $120 |
| Ardelyx, Inc. | 5 | $116 |
| Astellas Pharma US Inc | 4 | $92 |
| Phathom Pharmaceuticals, Inc. | 3 | $81 |
| Exact Sciences | 4 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Baxter Healthcare | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Mission Pharmacal Company | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,392 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Epolamine | 792 | $570,650 |
| VascepaIcosapent Ethyl | 1,184 | $425,599 |
| Diclofenac Sodium | 335 | $238,794 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 163 | $204,639 |
| RestasisCyclosporine | 227 | $147,995 |
| CreonLipase/Protease/Amylase | 129 | $145,031 |
| JardianceEmpagliflozin | 195 | $124,861 |
| OzempicSemaglutide | 114 | $105,145 |
| RybelsusSemaglutide | 85 | $90,975 |
| JanuviaSitagliptin Phosphate | 150 | $89,206 |
| VemlidyTenofovir Alafenamide | 55 | $77,675 |
| ZenpepLipase/Protease/Amylase | 46 | $75,965 |
| MyrbetriqMirabegron | 145 | $74,221 |
| LinzessLinaclotide | 128 | $67,583 |
| Lactulose | 30 | $62,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Creon, Linzess, Ubrelvy | $626 | $397,413505 claims |
| Novo NordiskOzempic, Rybelsus | $738 | $196,120199 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $464 | $155,065245 claims |
| MerckJanuvia, Janumet | $242 | $128,026204 claims |
| GileadVemlidy | $1,749 | $77,67555 claims |
| Aimmune Therapeutics, Inc.Zenpep | $21 | $75,96546 claims |
| Astellas Pharma US IncMyrbetriq | $92 | $74,221145 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $120 | $61,693132 claims |
| AmgenProlia | $915 | $48,31528 claims |
| PfizerEliquis | $126 | $21,73635 claims |
| Lilly USA, LLCMounjaro | $226 | $13,49013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Flushing
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.